1. MacDonald MR, Tay WT, Teng TK, Anand I, Ling LH, Yap J,
et al. Regional variation of mortality in heart failure with
reduced and preserved ejection fraction across Asia: Outcomes
in the ASIAN-HF registry. J Am Heart Assoc 2020; 9: e012199.
2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach
A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and
treatment of acute and chronic heart failure: Developed by the
Task Force for the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology (ESC) with
the special contribution of the Heart Failure Association (HFA)
of the ESC. Rev Esp Cardiol (Engl Ed) 2022; 75: 523.
3. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt
MS, Callaway CW, et al. Heart disease and stroke statistics –
2021 update: A report from the American Heart Association.
Circulation 2021; 143: e254 – e743.
4. Fujimoto W, Toh R, Takegami M, Hayashi T, Kuroda K, Hatani
Y, et al. Estimating incidence of acute heart failure syndromes in
Japan: An analysis from the KUNIUMI Registry. Circ J 2021;
85: 1860 – 1868.
5. GBD 2015 Disease and Injury Incidence and Prevalence
Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries,
1990 – 2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545 – 1602.
6. Kannel WB, McGee DL. Diabetes and cardiovascular disease:
The Framingham study. JAMA 1979; 241: 2035 – 2038.
7. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart
failure in type 2 diabetes: Prevalence, incidence, and risk factors.
Diabetes Care 2001; 24: 1614 – 1619.
8. Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E,
Rosamond WD, et al. HbA1c as a risk factor for heart failure in
persons with diabetes: The Atherosclerosis Risk in Communities
(ARIC) study. Diabetologia 2008; 51: 2197 – 2204.
9. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai
AS, et al. Type 2 diabetes mellitus and heart failure: A scientific
statement from the American Heart Association and the Heart
Failure Society of America: This statement does not represent an
update of the 2017 ACC/AHA/HFSA heart failure guideline
update. Circulation 2019; 140: e294 – e324.
10. Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, Yun UJ,
Cooksey RC, et al. Impaired cardiac efficiency and increased
fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004; 53: 2366 – 2374.
11. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen
TS. Increased myocardial oxygen consumption reduces cardiac
efficiency in diabetic mice. Diabetes 2006; 55: 466 – 473.
12. Karwi QG, Ho KL, Pherwani S, Ketema EB, Sun Q, Lopaschuk
GD. Concurrent diabetes and heart failure: Interplay and novel
therapeutic approaches. Cardiovasc Res 2022; 118: 686 – 715.
13. Avogaro A, Bier DM. Contribution of 3-hydroxyisobutyrate to
the measurement of 3-hydroxybutyrate in human plasma: Comparison of enzymatic and gas-liquid chromatography-mass spectrometry assays in normal and in diabetic subjects. J Lipid Res
1989; 30: 1811 – 1817.
14. Mardinoglu A, Gogg S, Lotta LA, Stancakova A, Nerstedt A,
Boren J, et al. Elevated plasma levels of 3-hydroxyisobutyric acid
are associated with incident type 2 diabetes. EBioMedicine 2018;
27: 151 – 155.
15. Nilsen MS, Jersin RA, Ulvik A, Madsen A, McCann A, Svensson
PA, et al. 3-Hydroxyisobutyrate, a strong marker of insulin
resistance in type 2 diabetes and obesity that modulates white
and brown adipocyte metabolism. Diabetes 2020; 69: 1903 – 1916.
16. Asanuma H, Kitakaze M. The largest cohort study opens a new
era for the management of heart failure in Japan. Circ J 2011; 75:
775 – 776.
17. Irino Y, Toh R, Nagao M, Mori T, Honjo T, Shinohara M, et
al. 2-Aminobutyric acid modulates glutathione homeostasis in
the myocardium. Sci Rep 2016; 6: 36749.
18. Lamb HJ, Beyerbacht HP, van der Laarse A, Stoel BC, Doornbos
J, van der Wall EE, et al. Diastolic dysfunction in hypertensive
heart disease is associated with altered myocardial metabolism.
Circulation 1999; 99: 2261 – 2267.
19. Liao R, Nascimben L, Friedrich J, Gwathmey JK, Ingwall JS.
Decreased energy reserve in an animal model of dilated cardiomyopathy: Relationship to contractile performance. Circ Res
1996; 78: 893 – 902.
20. Neubauer S, Horn M, Pabst T, Godde M, Lubke D, Jilling B, et
al. Contributions of 31P-magnetic resonance spectroscopy to the
understanding of dilated heart muscle disease. Eur Heart J 1995;
16(Suppl O): 115 – 118.
21. Lommi J, Kupari M, Koskinen P, Naveri H, Leinonen H, Pulkki
K, et al. Blood ketone bodies in congestive heart failure. J Am
Coll Cardiol 1996; 28: 665 – 672.
22. Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z,
et al. Catabolic defect of branched-chain amino acids promotes
heart failure. Circulation 2016; 133: 2038 – 2049.
23. Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuzat M,
Testani JM, et al. Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support. J Am Coll Cardiol 2016; 67: 291 – 299.
24. Truby LK, Regan JA, Giamberardino SN, Ilkayeva O, Bain J,
Newgard CB, et al. Circulating long chain acylcarnitines and
outcomes in diabetic heart failure: An HF-ACTION clinical trial
substudy. Cardiovasc Diabetol 2021; 20: 161.
25. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin
resistance and risk of congestive heart failure. JAMA 2005; 294:
334 – 341.
26. Vardeny O, Gupta DK, Claggett B, Burke S, Shah A, Loehr L,
et al. Insulin resistance and incident heart failure the ARIC study
(Atherosclerosis Risk in Communities). JACC Heart Fail 2013;
1: 531 – 536.
27. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von
Haehling S, Okonko DO, et al. Impaired insulin sensitivity as an
independent risk factor for mortality in patients with stable
chronic heart failure. J Am Coll Cardiol 2005; 46: 1019 – 1026.
28. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien
LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to
insulin resistance. Cell Metab 2009; 9: 311 – 326.
29. Neinast MD, Jang C, Hui S, Murashige DS, Chu Q, Morscher
RJ, et al. Quantitative analysis of the whole-body metabolic fate
of branched-chain amino acids. Cell Metab 2019; 29: 417 – 429.
e4.
30. Tobias DK, Lawler PR, Harada PH, Demler OV, Ridker PM,
Manson JE, et al. Circulating branched-chain amino acids and
incident cardiovascular disease in a prospective cohort of US
women. Circ Genom Precis Med 2018; 11: e002157.
31. Jang C, Oh SF, Wada S, Rowe GC, Liu L, Chan MC, et al. A
branched-chain amino acid metabolite drives vascular fatty acid
transport and causes insulin resistance. Nat Med 2016; 22:
421 – 426.
32. Kedishvili NY, Popov KM, Jaskiewicz JA, Harris RA. Coordinated expression of valine catabolic enzymes during adipogenesis: Analysis of activity, mRNA, protein levels, and metabolic
consequences. Arch Biochem Biophys 1994; 315: 317 – 322.
Supplementary Files
Please find supplementary file(s);
https://doi.org/10.1253/circj.CJ-23-0577
Circulation Journal Vol.88, January 2024
...
論文の公開元へ
